The U.S. Food and Drug Administration (FDA) has approved a change to the labeled strength of Twirla, a weekly contraceptive patch, to more accurately reflect the amount of hormones—levonorgestrel and ethinyl estradiol—delivered to users. The update, announced by manufacturer Exeltis USA, aligns with recent clinical study data and FDA guidance, though users currently on the patch will not need to switch products. The revised labeling will appear on new packaging beginning in September 2024.
This adjustment comes as part of routine drug evaluation processes, where manufacturers must periodically update labeling to ensure it reflects the most current scientific understanding of a medication’s effects. For Twirla users, the change is largely administrative—meaning the patch itself remains the same—but it underscores the FDA’s commitment to transparency in contraceptive safety and efficacy.
Dr. Helena Fischer, Editor of Health at World Today Journal, notes that “contraceptive labeling updates are common as research evolves, but this one is notable because it directly addresses how hormone levels are communicated to both prescribers and users.” The update follows a similar 2023 revision to another weekly patch, Xulane, which adjusted its labeled strength for the same hormones.
–>
Why Is the FDA Adjusting Twirla’s Labeled Strength?
The FDA’s decision stems from new data from Study ATI-CL28, a clinical trial conducted by Exeltis to measure the actual hormone delivery rates of Twirla over its weekly wear period. According to the FDA’s draft guidance on contraceptive labeling, manufacturers must ensure that labeled hormone doses accurately represent what users receive. The study found that the patch delivers slightly different levels of levonorgestrel and ethinyl estradiol than previously labeled, prompting the revision.
Exeltis confirmed in a statement that the change is “consistent with the FDA’s expectations for precision in reproductive health products.” The company added that the patch’s effectiveness remains unchanged, as the adjustment is purely about labeling accuracy. “This update reflects our ongoing commitment to providing clear, science-backed information to healthcare providers and patients,” the statement read.
Key takeaway: The patch’s performance (e.g., pregnancy prevention rates) does not change, but the label will now reflect more precise hormone delivery data. Users should continue using their current patch until supplies run out; new packaging with the updated label will ship in September 2024.
What Does This Mean for Current Twirla Users?
For the approximately 200,000 U.S. women who use Twirla annually, the update has minimal practical impact. Here’s what to expect:
- No action needed: If you’re already using Twirla, you can continue with your current patch. The FDA and Exeltis emphasize that the patch’s contraceptive effectiveness is unchanged.
- New packaging in fall 2024: Starting in September or October, new boxes of Twirla will include the updated labeling. Pharmacies and healthcare providers will receive the revised stock in the coming months.
- Prescriber communication: Doctors may see the updated label when prescribing Twirla, but no clinical changes are required. The FDA notes that the revision is “informational” and does not alter dosing recommendations.
- Safety monitoring: The FDA will continue to track Twirla’s safety through its MedWatch system, as with all contraceptives.
Dr. Sarah Harper, an obstetrician-gynecologist at the Mayo Clinic, reassured users in a recent interview that “labeling updates are standard and don’t reflect a safety concern. The patch’s efficacy is well-established, and this change simply brings the label in line with what we now know about hormone delivery.”
How Does This Compare to Other Contraceptive Patch Updates?
The Twirla update follows a similar 2023 revision for Xulane, another weekly contraceptive patch. In that case, the FDA adjusted Xulane’s labeled strength after clinical studies showed discrepancies between the labeled and actual hormone levels. Both updates highlight the FDA’s increasing focus on precision dosing in hormonal contraceptives.
Comparison Table: Recent Contraceptive Patch Label Updates
| Patch Name | Update Reason | Effective Date | Impact on Users |
|---|---|---|---|
| Twirla | New clinical data (Study ATI-CL28) showed hormone delivery levels differed from labeled amounts. | September–October 2024 (new packaging) | None; current users unaffected. |
| Xulane | FDA review found labeled hormone doses did not match actual delivery. | June 2023 (new labeling) | None; patch efficacy unchanged. |
Both updates reflect the FDA’s broader trend of refining contraceptive labeling to ensure transparency. “This is part of a larger effort to modernize how we communicate about hormone-based methods,” said Dr. Harper. “Patients deserve to know exactly what they’re getting, and these adjustments help bridge any gaps between labeling and reality.”
What Should Users Do Next?
If you’re considering Twirla—or any contraceptive—here’s what to keep in mind:
- Check your patch’s expiration date: Twirla patches are stable for up to 3 years from manufacture. If your patch is near expiration, ask your pharmacist or provider for the updated version when restocking.
- Review the new label (when available): The updated packaging will include clearer details on hormone delivery rates. Exeltis has not yet released a side-by-side comparison, but the FDA’s guidance document outlines the expected changes.
- Discuss alternatives if concerned: If you’re unsure about Twirla’s suitability, consult your healthcare provider. Options include other patches (e.g., Xulane), birth control pills, or long-acting reversible contraceptives (LARCs) like IUDs or implants.
- Report side effects: As always, report any unusual symptoms to the FDA’s MedWatch program or your doctor.
Need More Information?
Visit the FDA’s contraceptive safety page or contact Exeltis directly at [email protected] for updated materials.
FAQ: Twirla Label Update—What You Need to Know
No. The update is purely about labeling accuracy. The patch’s contraceptive effectiveness remains the same.
The FDA requires manufacturers to update labels when new clinical data (like Study ATI-CL28) shows discrepancies. Exeltis submitted the revised labeling in early 2024 after completing the study.
No. The FDA and Exeltis state that the patch’s safety profile is unchanged. The update ensures users and providers have the most accurate information.
You can, but there’s no medical reason to switch due to this labeling update. Both patches use similar hormones (levonorgestrel/ethinyl estradiol) and have comparable efficacy rates.
The new label will be available on Twirla packaging starting September 2024. Exeltis has not yet published a preview, but the FDA’s guidance outlines the expected changes.
What Happens Next?
The next checkpoint for Twirla users is the rollout of updated packaging in September–October 2024. Exeltis has not announced further clinical trials or labeling changes, but the FDA will continue to monitor the patch’s safety post-update. Users with questions are encouraged to consult their healthcare provider or contact Exeltis directly.
For broader context, the FDA is also reviewing contraceptive access policies in light of recent legal and political developments. While unrelated to Twirla’s update, these discussions may influence future labeling standards for reproductive health products.
Share Your Experience
Have you used Twirla or another contraceptive patch? What questions do you have about this update? Share your thoughts in the comments below or on X @WorldTodayJrnl.